PATENT CLAIM ANALYSIS

Application Number: 16229490
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["514", "364000"]

Abstract:
The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.

Claim (Index 15):
The method of  claim 13 , wherein the administering step comprises administering the hydrochloride salt of ozanimod to the mammalian subject.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 98.0
- Lexical Diversity: 1.24
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16017345', '16017303', '14261175', '15954131', '12387228']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7782047213282139
- 35 USC 102 Novelty (BERT): 0.6300950562743075
- Combined Prediction Score: 0.7633937548228233
- Mean Citation Score: 393.56899
- Max Citation Score: 658.6389999999999
- Similarity Product: 516.3202783349154

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test